Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar desktop iconMarkt Monitor

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,727   0,000   (0,00%) Dagrange 0,715 - 0,728 3.278.719   Gem. (3M) 4,8M

Pharming Oktober 2022

3.907 Posts
Pagina: «« 1 ... 102 103 104 105 106 ... 196 »» | Laatste | Omlaag ↓
  1. bollewieter 17 oktober 2022 16:39
    quote:

    Theo3 schreef op 17 oktober 2022 15:33:

    die horde over de Euro heen is toch een ferme hobbel moeilijk te nemen als ik naar de borden op beurzen kijk en zie wat pharming erbij krijgt is het om te huilen maar laat hem maar eens het rood in gaan dan krijgt hij de bocht niet gehaald om voor te blijven
    Daar gaat hij over de bobbel
  2. forum rang 7 Janssen&Janssen 17 oktober 2022 20:06
    A new study revealed high levels of satisfaction among patients with hereditary angioedema (HAE) who switched from injectable prophylactic treatments to berotralstat (Orladeyo®) monotherapy. The results of the study are being presented as a poster at the National Organization for Rare Disorders’ Rare Disease and Orphan Products Breakthrough Summit.

    www.rarediseaseadvisor.com/conference...

    This study included 120 patients (114 adults and 6 children 12 years and over) with type I or II HAE who experienced at least two investigator-confirmed attacks within the first 8 weeks of the run-in period and took at least one dose of study treatment. Nine patients were aged = 65 years. Patients were randomised into 1 of 3 parallel treatment arms, stratified by baseline attack rate, in a 1:1:1 ratio (berotralstat 110 mg, berotralstat 150 mg or placebo by oral administration once daily, with food) for the 24-week treatment period.
    7 / 13

    A total of 81 patients received at least one dose of berotralstat in the 24-week treatment period. Overall, 66% of patients were female and 93% of patients were Caucasian with a mean age of 41.6 years. A history of laryngeal angioedema attacks was reported in 74% of patients and 75% reported prior use of long-term prophylaxis. The median attack rate during the prospective run-in period (baseline attack rate) was 2.9 per month. Of patients enrolled, 70% had a baseline attack rate of = 2 attacks per month.
    Patients discontinued other prophylactic HAE medicinal products prior to entering the study; however, all patients were allowed to use rescue medicinal products for treatment of breakthrough HAE attacks. In berotralstat-treated patients, 51.4% of breakthrough attacks were treated with C1-INH (see section "Warnings and precautions"). Concomitant use of C1-INH and berotralstat did not result in any identifiable adverse reactions.

    www.swissmedic.ch/dam/swissmedic/it/d...

    Orladeyo —> Ruconest goeije combi
  3. forum rang 8 BassieNL 17 oktober 2022 20:36
    quote:

    Janssen&Janssen schreef op 17 oktober 2022 20:06:

    A new study revealed high levels of satisfaction among patients with hereditary angioedema (HAE) who switched from injectable prophylactic treatments to berotralstat (Orladeyo®) monotherapy. The results of the study are being presented as a poster at the National Organization for Rare Disorders’ Rare Disease and Orphan Products Breakthrough Summit.

    www.rarediseaseadvisor.com/conference...

    This study included 120 patients (114 adults and 6 children 12 years and over) with type I or II HAE who experienced at least two investigator-confirmed attacks within the first 8 weeks of the run-in period and took at least one dose of study treatment. Nine patients were aged = 65 years. Patients were randomised into 1 of 3 parallel treatment arms, stratified by baseline attack rate, in a 1:1:1 ratio (berotralstat 110 mg, berotralstat 150 mg or placebo by oral administration once daily, with food) for the 24-week treatment period.
    7 / 13

    A total of 81 patients received at least one dose of berotralstat in the 24-week treatment period. Overall, 66% of patients were female and 93% of patients were Caucasian with a mean age of 41.6 years. A history of laryngeal angioedema attacks was reported in 74% of patients and 75% reported prior use of long-term prophylaxis. The median attack rate during the prospective run-in period (baseline attack rate) was 2.9 per month. Of patients enrolled, 70% had a baseline attack rate of = 2 attacks per month.
    Patients discontinued other prophylactic HAE medicinal products prior to entering the study; however, all patients were allowed to use rescue medicinal products for treatment of breakthrough HAE attacks. In berotralstat-treated patients, 51.4% of breakthrough attacks were treated with C1-INH (see section "Warnings and precautions"). Concomitant use of C1-INH and berotralstat did not result in any identifiable adverse reactions.

    www.swissmedic.ch/dam/swissmedic/it/d...

    Orladeyo —> Ruconest goeije combi
    Ik zou zeggen, probeer de Ruconest licentie aan BioCryst te verkopen!
    Kunnen ze een totaal pakket aanbieden (profylaxe + doorbraak).

    Of wacht even tot de goedkeuring voor leniolisib er is. Dan kunnen ze alles overnemen.
    Houd de productie en de konijnen in NL, want hier zit de expertise + vergunningen.
    De business zit in de VS.
  4. [verwijderd] 17 oktober 2022 21:30
    quote:

    BassieNL schreef op 17 oktober 2022 20:36:

    [...]
    Ik zou zeggen, probeer de Ruconest licentie aan BioCryst te verkopen!
    Kunnen ze een totaal pakket aanbieden (profylaxe + doorbraak).

    Of wacht even tot de goedkeuring voor leniolisib er is. Dan kunnen ze alles overnemen.
    Houd de productie en de konijnen in NL, want hier zit de expertise + vergunningen.
    De business zit in de VS.
    Ik zou zeggen, probeer de Ruconest licentie aan BioCryst te verkopen!
    Kunnen ze een totaal pakket aanbieden (profylaxe + doorbraak).


    Goed idee!
3.907 Posts
Pagina: «« 1 ... 102 103 104 105 106 ... 196 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.